Invention Grant
- Patent Title: CDK9 as modifier of the IGF pathway and methods of use
- Patent Title (中): CDK9作为IGF途径的修饰剂和使用方法
-
Application No.: US11628636Application Date: 2005-06-20
-
Publication No.: US08758994B2Publication Date: 2014-06-24
- Inventor: Mark E. Maxwell , Michael Martin Ollmann , Timothy S. Heuer , Lynn Margaret Bjerke
- Applicant: Mark E. Maxwell , Michael Martin Ollmann , Timothy S. Heuer , Lynn Margaret Bjerke
- Applicant Address: US CA South San Francisco
- Assignee: Exelixis, Inc.
- Current Assignee: Exelixis, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- International Application: PCT/US2005/021630 WO 20050620
- International Announcement: WO2006/009933 WO 20060126
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/53
Abstract:
Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of CDK9 are provided.
Public/Granted literature
- US20080095763A1 Cdk9 as Modifier of the Igf Pathway and Methods of Use Public/Granted day:2008-04-24
Information query
